TRIB3	B:C1259051
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	B:C0013081
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	B:C0013089
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	B:C0596402
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	B:C0024623
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	B:C0334227
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	B:C1259051
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	B:C0033684
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	B:C1327622
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B:C0087111
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	B:C0920425
of	O
human	O
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	B:C0086418
tumors	O
.	O

TRIB3	O
downregulation	O
enhances	O
doxorubicin	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
cancer	I:C0024623
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	I:C1327622
pro-survival	I:C1327622
pathways	I:C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
human	O
tumors	B:C0027651
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	B:C0006826
is	O
controversial	O
,	O
as	O
TRIB3	O
protein	O
levels	I:C0428479
have	O
been	O
associated	O
with	O
both	O
good	O
and	O
poor	O
prognosis	I:C0278252
in	O
cancer	O
patients	O
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	O
is	O
controversial	O
,	O
as	O
TRIB3	B:C1259051
protein	O
levels	I:C0428479
have	O
been	O
associated	O
with	O
both	O
good	O
and	O
poor	O
prognosis	I:C0278252
in	O
cancer	O
patients	O
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	O
is	O
controversial	O
,	O
as	O
TRIB3	O
protein	B:C0428479
levels	I:C0428479
have	O
been	O
associated	O
with	O
both	O
good	O
and	O
poor	O
prognosis	I:C0278252
in	O
cancer	O
patients	O
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	O
is	O
controversial	O
,	O
as	O
TRIB3	O
protein	O
levels	I:C0428479
have	O
been	O
associated	O
with	O
both	O
good	B:C0278250
and	O
poor	O
prognosis	I:C0278252
in	O
cancer	O
patients	O
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	O
is	O
controversial	O
,	O
as	O
TRIB3	O
protein	O
levels	I:C0428479
have	O
been	O
associated	O
with	O
both	O
good	O
and	O
poor	B:C0278252
prognosis	I:C0278252
in	O
cancer	O
patients	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	B:C1259051
expression	O
in	O
the	O
survival	O
of	O
gastric	O
cancer	I:C0024623
cells	O
exposed	O
to	O
anticancer	O
drugs	I:C0003392
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	B:C1171362
in	O
the	O
survival	O
of	O
gastric	O
cancer	I:C0024623
cells	O
exposed	O
to	O
anticancer	O
drugs	I:C0003392
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	O
in	O
the	O
survival	B:C0007620
of	O
gastric	O
cancer	I:C0024623
cells	O
exposed	O
to	O
anticancer	O
drugs	I:C0003392
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	O
in	O
the	O
survival	O
of	O
gastric	B:C0024623
cancer	I:C0024623
cells	O
exposed	O
to	O
anticancer	O
drugs	I:C0003392
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	O
in	O
the	O
survival	O
of	O
gastric	O
cancer	I:C0024623
cells	B:C0334227
exposed	O
to	O
anticancer	O
drugs	I:C0003392
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	O
in	O
the	O
survival	O
of	O
gastric	O
cancer	I:C0024623
cells	O
exposed	O
to	O
anticancer	B:C0003392
drugs	I:C0003392
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	B:C0003392
drug	I:C0003392
,	O
doxorubicin	O
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	O
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	O
drug	I:C0003392
,	O
doxorubicin	B:C0013089
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	O
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	O
drug	I:C0003392
,	O
doxorubicin	O
,	O
induced	O
cytotoxicity	B:C0596402
by	O
decreasing	O
TRIB3	O
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	O
drug	I:C0003392
,	O
doxorubicin	O
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	B:C1540055
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	O
drug	I:C0003392
,	O
doxorubicin	O
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	O
transcription	B:C0040649
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	I:C0162638
death	I:C0162638
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	O
drug	I:C0003392
,	O
doxorubicin	O
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	O
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	B:C0162638
cell	I:C0162638
death	I:C0162638
.	O

Moreover	O
,	O
TRIB3	B:C1099354
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	B:C2350567
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	B:C0013089
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	B:C0162638
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	B:C0024623
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	B:C0334227
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	B:C1171362
of	O
downstream	O
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	B:C0522506
apoptotic	O
factors	I:C0763396
.	O

Moreover	O
,	O
TRIB3	O
siRNA	I:C1099354
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
in	O
gastric	O
cancer	I:C0024623
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	B:C0763396
factors	I:C0763396
.	O

Conversely	O
,	O
overexpression	B:C1514559
of	O
TRIB3	O
significantly	O
protected	O
cells	I:C0007634
against	O
doxorubicin	O
-	O
induced	O
apoptosis	O
.	O

Conversely	O
,	O
overexpression	O
of	O
TRIB3	B:C1259051
significantly	O
protected	O
cells	I:C0007634
against	O
doxorubicin	O
-	O
induced	O
apoptosis	O
.	O

Conversely	O
,	O
overexpression	O
of	O
TRIB3	O
significantly	O
protected	B:C0007634
cells	I:C0007634
against	O
doxorubicin	O
-	O
induced	O
apoptosis	O
.	O

Conversely	O
,	O
overexpression	O
of	O
TRIB3	O
significantly	O
protected	O
cells	I:C0007634
against	O
doxorubicin	B:C0013089
-	O
induced	O
apoptosis	O
.	O

Conversely	O
,	O
overexpression	O
of	O
TRIB3	O
significantly	O
protected	O
cells	I:C0007634
against	O
doxorubicin	O
-	O
induced	O
apoptosis	B:C0162638
.	O

Our	O
results	O
indicate	O
that	O
downregulation	B:C0013081
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	B:C1259051
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	B:C0007587
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	B:C0013089
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	B:C0162638
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	B:C2986514
role	O
of	O
TRIB3	O
.	O

Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	I:C0007587
and	O
enhance	O
doxorubicin	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti-apoptotic	O
role	O
of	O
TRIB3	B:C1259051
.	O

The	O
inductions	B:C0017391
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	B:C0752312
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	B:C0013089
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	B:C1259051
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	B:C0013081
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	B:C1259051
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	B:C1514559
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	B:C0013089
-	O
induced	O
MAPK	O
activation	I:C1155551
.	O

The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	O
-	O
mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	O
-	O
induced	O
MAPK	B:C1155551
activation	I:C1155551
.	O

In	O
sum	O
,	O
our	O
findings	B:C2825141
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	B:C1259051
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	B:C2986514
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	B:C0013089
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	B:C0024623
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	B:C0334227
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	B:C1259051
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	B:C1171362
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	B:C0003392
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	B:C0013089
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	B:C0123931
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	B:C0069717
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	O
therapy	I:C0920425
.	O

In	O
sum	O
,	O
our	O
findings	O
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti-apoptotic	O
role	O
in	O
doxorubicin	O
-	O
treated	O
gastric	O
cancer	I:C0024623
cell	O
lines	I:C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	O
drugs	I:C0003392
,	O
such	O
as	O
doxorubicin	O
,	O
irinotecan	O
or	O
oxaliplatin	O
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B:C0920425
therapy	I:C0920425
.	O

